Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaboration with Pfizer

By Rene Pretorius

February 28, 2025

Ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, is showing significant promise in treating non-small cell lung cancer (NSCLC) and other solid tumors. Recent ivonescimab clinical trials have demonstrated its ability to enhance progression-free survival (PFS) and objective response rates (ORR), positioning it as a strong contender in the evolving oncology landscape.

Breakthrough Clinical Trials

Ivonescimab’s potential has been validated in multiple phase 3 trials:

  • HARMONi-A Trial: This study assessed ivonescimab combined with chemotherapy in EGFR-mutated NSCLC patients who had progressed on tyrosine kinase inhibitors (TKIs). The results were compelling:
    • Median PFS: 7.1 months (vs. 4.8 months for placebo).
    • ORR: 50.6% (vs. 35.4%).
    • Safety: Adverse events were manageable and mostly related to chemotherapy.
  • HARMONi-2 Trial: This trial evaluated ivonescimab monotherapy against pembrolizumab in PD-L1–positive advanced NSCLC.
    • Median PFS: 11.14 months (vs. 5.82 months for pembrolizumab).
    • ORR: 50.0% (vs. 38.5%).
    • Safety: Comparable to pembrolizumab, with no new safety concerns.

These results reinforce ivonescimab’s ability to outperform existing standards of care in key NSCLC subpopulations.

A Game-Changing Collaboration with Pfizer

Building on this success, Summit Therapeutics has entered into a strategic collaboration with Pfizer to further explore ivonescimab’s potential. The goal is to evaluate the combination of ivonescimab with Pfizer’s vedotin-based antibody-drug conjugates (ADCs) across multiple solid tumor settings.

Key Aspects of the Partnership

  • Objective. Assess the safety and anti-tumor activity of ivonescimab when combined with Pfizer’s ADCs, with a focus on NSCLC and other solid tumors.
  • Roles. Summit provides ivonescimab, while Pfizer leads the clinical trials, ensuring rigorous evaluation.
  • Clinical Trials. Studies are expected to begin in mid-2024, with further details to follow.
  • Innovation Potential. Combining ivonescimab’s dual targeting mechanism with Pfizer’s ADCs could overcome resistance mechanisms that limit current monotherapies, offering a novel approach to cancer treatment.

Scientific and Market Implications

Ivonescimab, also known as SMT112 (Summit’s license territories) and AK112 (China/Australia), is designed with cooperative PD-1/VEGF binding, leveraging a tetravalent structure to enhance tumor microenvironment avidity. With over 2,300 patients treated globally, its clinical development is advancing rapidly.

This collaboration with Pfizer presents several strategic benefits:

  • Market Expansion. Targets multiple solid tumor types, increasing ivonescimab’s commercial potential.
  • Accelerated Development. Pfizer’s expertise could fast-track clinical timelines, with early efficacy data expected by 2026.
  • Competitive Positioning. Success will depend on demonstrating superior efficacy and safety compared to existing therapies, positioning ivonescimab in the highly competitive oncology space.

By integrating cutting-edge science with strategic industry partnerships, ivonescimab is poised to reshape the landscape of targeted cancer therapies. The coming years will be crucial in determining its full potential, but current data suggests it could become a cornerstone in the fight against NSCLC and beyond.

Reference url

Recent Posts

Donanemab Alzheimer’s Approval: A New Era in Treatment

By João L. Carapinha

August 8, 2025

The EMA granted marketing authorization for donanemab, a monoclonal antibody targeting beta-amyloid plaques. It treats early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid pathology). This approval highlights donanemab's role in Alzheimer's trea...
AI in Real-World Evidence: Insights from Mitch Higashi

By Staff Writer

August 7, 2025

In this update, we review the Q&A with Mitch Higashi, PhD, ISPOR’s Associate Chief Science Officer published on Pharmalive. It discusses AI in Real-World Evidence (RWE) and health technology assessments (HTA). Key themes include AI-driven early disease detection and NLP tackling unstructured ...
Achieving International Drug Price Parity: Trump’s Mandate
President Donald J. Trump’s July 31, 2025 fact sheet outlines a sweeping policy initiative to enforce international drug price parity. It aims to compel pharmaceutical companies to lower U.S. prescription drug prices to match the lowest prices offered in other developed nations. This policy intro...